降糖药在超重/肥胖多囊卵巢综合征患者治疗中的研究进展
Research Progress of Antidiabetic Drugs in the Treatment of Overweight/Obese Patients with Polycystic Ovarian Syndrome
DOI: 10.12677/ACM.2023.1391943, PDF,   
作者: 杨宇萱, 刘东方*：重庆医科大学附属第二医院内分泌代谢科，重庆
关键词: 降糖药；超重；肥胖；多囊卵巢综合征；治疗；Antidiabetic Drugs； Overweight； Obese； Polycystic Ovarian Syndrome； Therapy
摘要: 多囊卵巢综合征是一种常见且复杂的内分泌疾病，在育龄期女性中患病人群占1/10左右。多囊卵巢综合征患者中合并超重或肥胖者占比超过一半，且该部分人群代谢和生殖方面问题往往更严重且对治疗反应性较差，该类人群的代谢治疗方案探索成为研究的热点和难点。目前多囊卵巢综合征代谢调整治疗药物主要有二甲双胍、噻唑烷二酮类和阿卡波糖，近年来胰高血糖素样肽-1类似物和钠葡萄糖共转运蛋白-2抑制剂两类降糖药也逐渐被用于超重/肥胖PCOS患者的代谢调整治疗。本文主要就超重/肥胖PCOS患者代谢治疗药物的研究进展作一综述。
Abstract: Polycystic ovarian syndrome (PCOS) is a common and complex reproductive endocrine disorder during the childbearing age in female with a prevalence of about 10%. Overweight and obesity are common comorbidities among females with PCOS, who account for more than 50%. Overweight/ Obese patients often have worse symptoms and are less responsive to treatment. Seeking more ef-fective treatment means in metabolic dysfunctions and reproductive abnormalities for these people is a hotspot and difficult point in medical research nowadays. There are three main types of antidi-abetic drugs that are used to treat PCOS, including metformin, thiazolidinedione and acarbose. Re-cently, glucagon-like peptide 1 (GLP-1) analogues and sodium-glucose co-transporter-2 (SGLT-2) in-hibitors are progressively used in the treatment of overweight/obese patients with PCOS. This re-view article aims to summarize the recent development of antidiabetic drugs in overweight/ obese patients with PCOS.
文章引用：杨宇萱, 刘东方. 降糖药在超重/肥胖多囊卵巢综合征患者治疗中的研究进展[J]. 临床医学进展, 2023, 13(9): 13901-13907. https://doi.org/10.12677/ACM.2023.1391943

参考文献

[1] Joham, A.E., Norman, R.J., Stener-Victorin, E., et al. (2022) Polycystic Ovary Syndrome. The Lancet Diabetes & En-docrinology, 10, 668-680. [Google Scholar] [CrossRef] 
[2] Kakoly, N.S., Earnest, A., Teede, H.J., et al. (2019) The Impact of Obesity on the Incidence of Type 2 Diabetes among Women with Polycystic Ovary Syndrome. Diabetes Care, 42, 560-567. [Google Scholar] [CrossRef] [PubMed]
[3] Wekker, V., van Dammen, L., Koning, A., et al. (2020) Long-Term Cardiometabolic Disease Risk in Women with PCOS: A Systematic Review and Meta-Analysis. Human Reproduction Update, 26, 942-960. [Google Scholar] [CrossRef] [PubMed]
[4] Barry, J.A., Azizia, M.M. and Hardiman, P.J. (2014) Risk of En-dometrial, Ovarian and Breast Cancer in Women with Polycystic Ovary Syndrome: A Systematic Review and Me-ta-Analysis. Human Reproduction Update, 20, 748-758. [Google Scholar] [CrossRef] [PubMed]
[5] Persson, S., Elenis, E., Turkmen, S., et al. (2021) Higher Risk of Type 2 Diabetes in Women with Hyperandrogenic Polycystic Ovary Syndrome. Fertility and Sterility, 116, 862-871. [Google Scholar] [CrossRef] [PubMed]
[6] Liu, Q., Tang, B., Zhu, Z., et al. (2022) A Genome-Wide Cross-Trait Analysis Identifies Shared Loci and Causal Relationships of Type 2 Diabetes and Glycaemic Traits with Pol-ycystic Ovary Syndrome. Diabetologia, 65, 1483-1494. [Google Scholar] [CrossRef] [PubMed]
[7] Escobar-Morreale, H.F. (2018) Polycystic Ovary Syndrome: Definition, Aetiology, Diagnosis and Treatment. Nature Reviews Endocrinology, 14, 270-284. [Google Scholar] [CrossRef] [PubMed]
[8] Joo, Y.Y., Actkins, K., Pacheco, J.A., et al. (2020) A Polygenic and Phenotypic Risk Prediction for Polycystic Ovary Syndrome Evaluated by Phenome-Wide Association Studies. The Journal of Clinical Endocrinology & Metabolism, 105, 1918-1936. [Google Scholar] [CrossRef] [PubMed]
[9] Liu, Q., Zhu, Z., Kraft, P., et al. (2022) Genomic Correlation, Shared Loci, and Causal Relationship between Obesity and Polycystic Ovary Syndrome: A Large-Scale Genome-Wide Cross-Trait Analysis. BMC Medicine, 20, Article No. 66. [Google Scholar] [CrossRef] [PubMed]
[10] Cena, H., Chiovato, L. and Nappi, R.E. (2020) Obesity, Poly-cystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists. The Journal of Clinical Endocri-nology & Metabolism, 105, e2695-e2709. [Google Scholar] [CrossRef] [PubMed]
[11] Zhang, H., Wang, W., Zhao, J., et al. (2022) Relationship between Body Composition, Insulin Resistance, and Hormonal Profiles in Women with Polycystic Ovary Syndrome. Frontiers in Endocrinology (Lausanne), 13, Article ID: 1085656. [Google Scholar] [CrossRef] [PubMed]
[12] Glueck, C.J. and Goldenberg, N. (2019) Characteristics of Obesity in Polycystic Ovary Syndrome: Etiology, Treatment, and Genetics. Metabolism, 92, 108-120. [Google Scholar] [CrossRef] [PubMed]
[13] Wu, L., Fang, Q., Wang, M., et al. (2022) Effect of Weight Loss on Pregnancy Outcomes, Neuronal-Reproductive- Metabolic Hormones and Gene Expres-sion Profiles in Granulosa Cells in Obese Infertile PCOS Patients Undergoing IVF-ET. Frontiers in Endocrinology (Lausanne), 13, Article ID: 954428. [Google Scholar] [CrossRef] [PubMed]
[14] Visser, J.A. (2021) The Im-portance of Metabolic Dysfunction in Polycystic Ovary Syndrome. Nature Reviews Endocrinology, 17, 77-78. [Google Scholar] [CrossRef] [PubMed]
[15] Zeng, X., Xie, Y.J., Liu, Y.T., et al. (2020) Polycystic Ovarian Syndrome: Correlation between Hyperandrogenism, Insulin Resistance and Obesity. Clinica Chimica Acta, 502, 214-221. [Google Scholar] [CrossRef] [PubMed]
[16] de Medeiros, S.F., Rodgers, R.J. and Norman, R.J. (2021) Adipo-cyte and Steroidogenic Cell Cross-Talk in Polycystic Ovary Syndrome. Human Reproduction Update, 27, 771-796. [Google Scholar] [CrossRef] [PubMed]
[17] Velazquez, E.M., Mendoza, S., Hamer, T., et al. (1994) Metformin Therapy in Polycystic Ovary Syndrome Reduces Hyperinsulinemia, Insulin Resistance, Hyperandrogenemia, and Systol-ic Blood Pressure, While Facilitating Normal Menses and Pregnancy. Metabolism, 43, 647-654. [Google Scholar] [CrossRef] [PubMed]
[18] Lord, J.M., Flight, I.H. and Norman, R.J. (2003) Metformin in Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis. BMJ, 327, 951-953. [Google Scholar] [CrossRef] [PubMed]
[19] Li, X., Celotto, S., Pizzol, D., et al. (2021) Metformin and Health Outcomes: An Umbrella Review of Systematic Reviews with Meta-Analyses. European Journal of Clinical Investigation, 51, e13536. [Google Scholar] [CrossRef] [PubMed]
[20] Garcia-Gomez, E., Gomez-Viais, Y.I., Cruz-Aranda, M.M., et al. (2023) The Effect of Metformin and Carbohydrate-Controlled Diet on DNA Methylation and Gene Expression in the Endometrium of Women with Polycystic Ovary Syndrome. International Journal of Molecular Sciences, 24, Article No. 6857. [Google Scholar] [CrossRef] [PubMed]
[21] Orostica, M.L., Astorga, I., Plaza-Parrochia, F., et al. (2022) Metformin Treatment Regulates the Expression of Molecules Involved in Adiponectin and Insulin Signaling Pathways in Endometria from Women with Obesity-Associated Insulin Resistance and PCOS. International Journal of Molecular Sciences, 23, Article No. 3922. [Google Scholar] [CrossRef] [PubMed]
[22] Lovvik, T.S., Carlsen, S.M., Salvesen, O., et al. (2019) Use of Metfor-min to Treat Pregnant Women with Polycystic Ovary Syndrome (PregMet2): A Randomised, Double-Blind, Place-bo-Controlled Trial. The Lancet Diabetes & Endocrinology, 7, 256-266. [Google Scholar] [CrossRef] 
[23] Li, Y., Tan, J., Wang, Q., et al. (2020) Comparing the Indi-vidual Effects of Metformin and Rosiglitazone and Their Combination in Obese Women with Polycystic Ovary Syn-drome: A Randomized Controlled Trial. Fertility and Sterility, 113, 197-204. [Google Scholar] [CrossRef] [PubMed]
[24] Zhao, H., Wang, D., Xing, C., et al. (2023) Pioglitazone Can Improve Liver Sex Hormone-Binding Globulin Levels and Lipid Metabolism in Polycystic Ovary Syndrome by Regu-lating Hepatocyte Nuclear Factor-4α. The Journal of Steroid Biochemistry and Molecular Biology, 229, Article ID: 106265. [Google Scholar] [CrossRef] [PubMed]
[25] Penna, I.A., Canella, P.R., Reis, R.M., et al. (2005) Acarbose in Obese Patients with Polycystic Ovarian Syndrome: A Double-Blind, Randomized, Placebo-Controlled Study. Human Reproduction, 20, 2396-2401. [Google Scholar] [CrossRef] [PubMed]
[26] Sonmez, A.S., Yasar, L., Savan, K., et al. (2005) Comparison of the Effects of Acarbose and Metformin Use on Ovulation Rates in Clomiphene Citrate-Resistant Polycystic Ovary Syndrome. Human Reproduction, 20, 175-179. [Google Scholar] [CrossRef] [PubMed]
[27] Araujo, P.I., Canella, P.R., Vieira, C.S., et al. (2007) Cardiovascular Risk Factors Are Reduced with a Low Dose of Acarbose in Obese Patients with Polycystic Ovary Syndrome. Fertility and Sterility, 88, 519-522. [Google Scholar] [CrossRef] [PubMed]
[28] Wang, X., Xu, T., Liu, R., et al. (2021) High-Fiber Diet or Combined with Acarbose Alleviates Heterogeneous Phenotypes of Polycystic Ovary Syndrome by Regulating Gut Mi-crobiota. Frontiers in Endocrinology (Lausanne), 12, Article ID: 806331. [Google Scholar] [CrossRef] [PubMed]
[29] Bednarz, K., Kowalczyk, K., Cwynar, M., et al. (2022) The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome. International Journal of Molecular Sciences, 23, Article No. 4334. [Google Scholar] [CrossRef] [PubMed]
[30] Wu, L.M., Wang, Y.X., Zhan, Y., et al. (2021) Dulaglutide, a Long-Acting GLP-1 Receptor Agonist, Can Improve Hyper-androgenemia and Ovarian Function in DHEA-Induced PCOS Rats. Peptides, 145, Article ID: 170624. [Google Scholar] [CrossRef] [PubMed]
[31] Zhang, Y., Lin, Y., Li, G., et al. (2023) Glucagon-Like Pep-tide-1 Receptor Agonists Decrease Hyperinsulinemia and Hyperandrogenemia in Dehydroepiandrosterone-Induced Pol-ycystic Ovary Syndrome Mice and Are Associated with Mitigating Inflammation and Inducing Browning of White Adi-pose Tissuedagger. Biology of Reproduction, 108, 945-959. [Google Scholar] [CrossRef] [PubMed]
[32] Yang, S., Zhao, L., He, W., et al. (2022) The Effect of Oral Antidiabetic Drugs on Improving the Endocrine and Metabolic States in Women with Polycystic Ovary Syndrome: A Systematic Review and Network Meta-Analysis. Drugs, 82, 1469-1480. [Google Scholar] [CrossRef] [PubMed]
[33] Zhang, Y., Qu, Z., Lu, T., et al. (2023) Effects of a Dulaglutide plus Calorie-Restricted Diet versus a Calorie-Restricted Diet on Visceral Fat and Metabolic Profiles in Women with Pol-ycystic Ovary Syndrome: A Randomized Controlled Trial. Nutrients, 15, Article No. 556. [Google Scholar] [CrossRef] [PubMed]
[34] Salamun, V., Jensterle, M., Janez, A., et al. (2018) Liraglutide Increases IVF Pregnancy Rates in Obese PCOS Women with Poor Response to First-Line Reproductive Treatments: A Pilot Ran-domized Study. European Journal of Endocrinology, 179, 1-11. [Google Scholar] [CrossRef] 
[35] Xing, C., Zhao, H., Zhang, J., et al. (2022) Effect of Metformin versus Metformin plus Liraglutide on Gonadal and Metabolic Profiles in Overweight Patients with Polycystic Ovary Syndrome. Frontiers in Endocrinology (Lausanne), 13, Article ID: 945609. [Google Scholar] [CrossRef] [PubMed]
[36] Ma, R.L., Deng, Y., Wang, Y.F., et al. (2021) Short-Term Combined Treatment with Exenatide and Metformin for Overweight/Obese Women with Polycystic Ovary Syndrome. Chinese Medical Journal (England), 134, 2882-2889. [Google Scholar] [CrossRef] 
[37] Elkind-Hirsch, K.E., Chappell, N., Shaler, D., et al. (2022) Liraglutide 3 mg on Weight, Body Composition, and Hormonal and Metabolic Parameters in Women with Obesity and Polycystic Ovary Syndrome: A Randomized Placebo-Controlled-Phase 3 Study. Fertility and Sterility, 118, 371-381. [Google Scholar] [CrossRef] [PubMed]
[38] Pruett, J.E., Torres, F.E., Everman, S.J., et al. (2021) Impact of SGLT-2 Inhibition on Cardiometabolic Abnormalities in a Rat Model of Polycystic Ovary Syndrome. International Journal of Molecular Sciences, 22, Article No. 2576. [Google Scholar] [CrossRef] [PubMed]
[39] Cai, M., Shao, X., Xing, F., et al. (2022) Efficacy of Canagliflozin ver-sus Metformin in Women with Polycystic Ovary Syndrome: A Randomized, Open-Label, Noninferiority Trial. Diabetes, Obesity and Metabolism, 24, 312-320. [Google Scholar] [CrossRef] [PubMed]
[40] Zhang, J., Xing, C., Cheng, X., et al. (2022) Canagliflozin Combined with Metformin versus Metformin Monotherapy for Endocrine and Metabolic Profiles in Overweight and Obese Women with Polycystic Ovary Syndrome: A Single-Center, Open-Labeled Prospective Randomized Controlled Trial. Frontiers in Endocrinology (Lausanne), 13, Article ID: 1003238. [Google Scholar] [CrossRef] [PubMed]

为你推荐